Venus Remedies Ltd Plunges to Lower Circuit Amid Heavy Selling Pressure

Intraday Price Action and Circuit Breaker Trigger

On 29 Dec 2025, Venus Remedies Ltd (Series BE) saw its share price plunge by ₹36.05, or 4.57%, touching an intraday low of ₹748.65 before settling at ₹752.00. This decline triggered the maximum permissible daily price band of 5%, activating the lower circuit breaker and halting further trading declines for the day. The stock’s weighted average price was notably closer to the day’s low, indicating that the bulk of trading volume occurred near the bottom end of the price band.

Volume and Liquidity Dynamics

Trading volume was relatively modest, with total traded volume at 0.24403 lakh shares, translating to a turnover of ₹1.86 crore. Despite the stock’s micro-cap status and limited liquidity, it remains sufficiently liquid for trades up to ₹0.06 crore based on 2% of its five-day average traded value. However, delivery volumes have sharply declined, with only 840 shares delivered on 26 Dec 2025, representing a 68.11% drop compared to the five-day average delivery volume. This suggests waning investor participation amid the recent price weakness.

Performance Relative to Sector and Market Benchmarks

Venus Remedies Ltd’s 1-day return of -4.69% significantly underperformed the Pharmaceuticals & Biotechnology sector’s marginal decline of -0.27% and the Sensex’s near-flat movement of -0.14%. Over the past three trading sessions, the stock has lost 7.59%, reflecting sustained selling pressure and a negative sentiment shift among investors. This underperformance highlights the stock’s vulnerability relative to its peers and the broader market environment.

Technical Indicators and Moving Averages

From a technical standpoint, the stock price remains above its 50-day, 100-day, and 200-day moving averages, signalling a longer-term uptrend. However, it is trading below its 5-day and 20-day moving averages, indicating short-term weakness and a potential correction phase. The recent price action suggests that short-term traders and momentum investors are retreating, possibly due to profit booking or concerns over near-term fundamentals.

Investor Sentiment and Market Psychology

The triggering of the lower circuit limit is often a sign of panic selling, where sellers overwhelm buyers, causing a sharp price drop that cannot be absorbed within the daily price band. In Venus Remedies Ltd’s case, the unfilled supply of shares at lower price levels indicates a lack of buying interest to stabilise the stock. This scenario can exacerbate negative sentiment, as investors rush to exit positions fearing further declines.

Fundamental and Market Context

Venus Remedies Ltd operates in the Pharmaceuticals & Biotechnology sector, a space that has seen mixed performance amid evolving regulatory and market dynamics. The company’s market capitalisation stands at ₹1,017 crore, categorising it as a micro-cap stock with inherent volatility and sensitivity to market news and sector trends. Despite the recent downgrade from a Hold to a Buy rating on 11 Nov 2025, reflected in its improved Mojo Grade of 77.0, the stock’s short-term price action suggests investors are cautious, possibly awaiting clearer catalysts or quarterly results.

Valuation and Quality Metrics

Venus Remedies Ltd holds a Market Cap Grade of 4, indicating moderate size and market presence within its sector. The Mojo Score of 77.0 and Buy grade reflect favourable fundamentals and growth prospects relative to peers. However, the recent price correction and circuit hit underscore the importance of monitoring liquidity and investor participation trends closely, as these factors can influence price stability and recovery potential.

Outlook and Investor Considerations

Investors should weigh the stock’s longer-term technical support levels against the current short-term weakness. The sustained selling pressure and circuit breaker activation highlight the risks of volatility in micro-cap stocks like Venus Remedies Ltd. While the company’s fundamentals remain intact, the market’s reaction suggests a need for caution and close observation of upcoming earnings, sector developments, and broader market sentiment before committing fresh capital.

Comparative Sector Performance and Risk Factors

Compared to its Pharmaceuticals & Biotechnology peers, Venus Remedies Ltd’s recent underperformance is notable. While the sector has experienced minor fluctuations, the stock’s sharper decline and circuit hit suggest company-specific concerns or profit-taking pressures. Investors should consider sector-wide trends such as regulatory changes, R&D pipeline progress, and competitive positioning when assessing the stock’s risk-reward profile.

Summary

Venus Remedies Ltd’s lower circuit hit on 29 Dec 2025 reflects a day of intense selling pressure and investor caution. The stock’s 4.57% intraday fall, combined with reduced delivery volumes and underperformance relative to sector and market benchmarks, signals a challenging near-term outlook. However, its solid fundamentals, improved Mojo Grade, and technical support from longer-term moving averages provide a foundation for potential recovery once market sentiment stabilises. Investors should remain vigilant and consider comprehensive research before making investment decisions in this volatile micro-cap stock.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →